Robert Komorowski, Ph.D is a Director of Clinical Development within the Neurology group at Ionis Pharmaceuticals supporting their clinical trials in Angelman syndrome. He is a neuroscientist by training who has spent the last 15 years studying rare genetic neurological disorders from both a pre-clinical and clinical perspective, with a focus on developing biomarkers and treatments for Angelman syndrome for the past 10 years. Robert is based in Massachusetts in the US.